Researchers present Phase II HIV gene therapy trial data at CROI 2010
Friday, February 19, 2010 - 05:28
in Health & Medicine
In the study, seven of eight subjects experienced a decrease in viral load set point and one subject experienced prolonged, complete control of HIV viremia for more than 14 weeks in the absence of HAART. The study looked at Lexgenleucel-T infusions in HIV-1 infected individuals prior to being taken off their antiretroviral treatment regimens as part of the study design's scheduled treatment interruption.